Dr. Oz and FDA Chief Say Biosimilar Drug Reform Will Lower Prices

Dr. Oz and FDA chief say biosimilar drug reform will lower prices

Trump administration officials pledged Monday that major reforms for biosimilar drug approvals will expand access and lower prices for some of the most expensive drugs on the market. Food and Drug Administration Commissioner Marty Makary and Centers for Medicare and Medicaid Services Administrator Mehmet Oz outlined further details about the Trump administration’s plan to slash regulations on biosimilar drug development in an op-ed on Monday. Th…

DR. MAKARY, DR OZ: People talk about lowering healthcare costs, but the Trump administration is doing it

FDA announces major biosimilar reforms to cut drug costs, removing extra clinical trial requirements that delay cheaper alternatives to $200,000 biologics by years.

FDA Takes Steps to Streamline Biosimilar Approvals and Lower Prescription Drug Costs

WASHINGTON, D.C. — The U.S. Food and Drug Administration has announced a series of measures intended to reduce the time and expense required to develop biosimilar drugs—lower-cost alternatives to biologic medications used to treat serious and chronic illnesses. The FDA’s new draft guidance, titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Effic…

‘What Is He Saying?’: Trump’s Absurd Brag Sets Off a Chain Reaction — Dr. Oz Takes the Bait, But Fumbles the Math, and Starts Unraveling Mid-Interview – Net News 1

Dr. Mehmet Oz jumped in to defend President Donald Trump’s wild claim about slashing drug prices by more than a…